Peritoneal fibrosis is one of the major causes of technical failure in patients on peritoneal dialysis (PD) for long period of time. Although the exact mechanisms of peritoneal damage during PD still remain unclear, generation of reactive oxygen species may be responsible for progressive membrane dysfunction. N-acetylcysteine (NAC)is a powerful antioxidant shown to protect peritoneal fibrosis in peritoneal dialysis animal model. In this study the researchers investigated the hypothesis that NAC protect peritoneal membrane damage.
N-Acetylcysteine (NAC) is known to be relatively safe and beneficial in peritoneal dialysis patient at a dose of 1200 mg per day. Patients will be randomly assigned to NAC and control group and prescribed according to the protocol. At 2 and 6 month, Peritoneal equilibrium test (PET) will be performed with blood sampling.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
66
N-acetylcysteine (200 mg/capsule) 1200 mg/day (600 mg bid) for 6 months
Ewha Womans University Mokdong Hospital
Seoul, South Korea
RECRUITINGPeritoneal membrane function
Changes in peritoneal membrane function (Δ D/Pcreatinine, ΔD/Purea) with peritoneal equilibrium test
Time frame: 6 months
Oxydative stress status
Measurement of oxydative stress status with plasma and RBC (GSH/GSSG, 8-OHdG)
Time frame: 6 months
Mesothelial cell transformation (Epithelial to Mesenchymal Transition)
Morphology was analysed with peritoneal dialysate isolated mesothelial cell
Time frame: 6 month
Residual renal function
Changes in residual renal function (ΔKt/Vurea, ΔeGFR)
Time frame: 6 month
Peritoneal membrane function
Changes in peritoneal membrane function (Δ D/Pcreatinine, ΔD/Purea) with peritoneal equilibrium test
Time frame: 2 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.